Longevity & Cellular Health research peptides

The short version

Supernova Peptides is a reading desk, not a store. It collects what the published research literature actually says about three agents that keep appearing in conversations about longevity and cellular health: Epitalon, MOTS-c, and NAD+. A peptide is a short chain of amino acids — the same building blocks as proteins, only far smaller — and both Epitalon and MOTS-c are peptides. NAD+ is not a peptide; it is a small molecule coenzyme present in every cell and often grouped with this research because of its central role in the same aging biology.

Each of these three has been studied because it may influence some aspect of how cells age: extending how long cells can divide, amplifying the body's metabolic stress response, or restoring coenzyme levels that decline with age. This desk does one job: it tells you, in plain language and with citations, what each compound was tested on, in which species, and how far that evidence actually reaches. A lot of it is in animals or cell cultures. None of these is an approved medicine for aging. This site does not sell anything, does not give medical advice, and never suggests a human dose.

What this desk covers

The theme here is geroprotection — compounds studied through the lens of slowing, preventing, or reversing cellular features of aging. The three agents approach that question from different directions, which is exactly why they sit together:

• Epitalon is the lead. It is a synthetic four-amino-acid peptide derived from research on the bovine pineal gland, studied primarily for its proposed effects on telomerase activation and the circadian neuroendocrine axis in aging. Its evidence base is largely Russian — specifically from the Khavinson laboratory — with limited independent replication in Western literature until 2024-2025 ^[1][2].
• MOTS-c is a 16-amino-acid peptide encoded not in the nuclear genome but in the mitochondrial genome. It operates as a metabolic stress sensor, activating AMPK and regulating antioxidant gene programs, and is studied as a potential exercise-mimetic regulator of age-related physical decline ^[10][11].
• NAD+ (nicotinamide adenine dinucleotide) is the cell's central electron carrier and a required substrate for signaling enzymes — sirtuins and PARPs — that govern DNA repair and gene regulation. Tissue NAD+ falls with age, and the research asks whether restoring it with precursors such as NMN or NR translates to measurable human benefit ^[16][13].

Read each compound page for the detailed evidence, or compare these peptides side by side.

The biology of aging: a brief frame

Aging is not a single process. Contemporary biology describes it as the gradual accumulation of molecular and cellular damage across several interdependent axes: telomere shortening (the protective caps on chromosomes erode with each cell division), mitochondrial dysfunction (energy generation becomes less efficient and more prone to oxidative damage), epigenetic drift (gene-regulation patterns shift away from youthful programs), NAD+ depletion (the coenzyme pool shrinks, starving DNA-repair enzymes of a substrate they need), and loss of proteostasis (cells accumulate misfolded proteins they can no longer clear).

The three agents on this desk each map to one or more of these axes. Epitalon is proposed to address telomere shortening and neuroendocrine circadian decline ^[1][4]. MOTS-c is a mitochondrial-encoded peptide that functions as a retrograde stress signal, potentially countering mitochondrial dysfunction and metabolic aging ^[10][12]. NAD+ sits at the intersection of cellular energetics, sirtuin-mediated gene regulation, and PARP-dependent DNA repair ^[16]. None of these is a proven cure for aging; each is a research avenue. That distinction is the starting point for every page here.

How this desk reads the literature

Supernova Peptides is a cross-referenced literature digest. Each compound page summarizes the peer-reviewed studies, cites them by number, and links to a single shared references list that aggregates every source across all three. Where the evidence is thin, single-lab, or preclinical only, this desk says so plainly. That caution is part of the record, not a footnote to it.

One convention matters for Epitalon in particular: a significant portion of its foundational research originates from a single Russian research program (Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology). This desk reports that work faithfully and without dismissal, but it also notes, wherever relevant, whether independent replication exists ^[1][4]. The goal across all three compounds is a quiet, accurate map of what is known — where the science is solid, where it rests on narrow preclinical data, and where the headline claims outpace the evidence.